Stephen Liu/LinkedIn
May 8, 2025, 17:31
Stephen V Liu highlights SYS6010 ADC Data in EGFR-mutant NSCLC at AACR25
Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Shun Lu showed data for SYS6010, an EGFR-targeting ADC, at AACR25. Small numbers but very encouraging efficacy in EGFR mutant NSCLC especially post-TKI but pre-chemotherapy with RR 63% (RR 89% at 4.8 mg/kg dose) with expected safety signals (myelosuppression).”
Learn more about EGFR-mutant NSCLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 17:31
May 8, 2025, 17:30
May 8, 2025, 15:53
May 8, 2025, 15:14
May 8, 2025, 15:13